S757 Efficacy and Safety of 2 Years of Continuous Ozanimod Treatment: Interim Analysis of the True North Open-Label Extension Study. (October 2022) - Dulai, Parambir; Dignass, Axel; Savarino, Edoardo; Hudesman, David; Afzali, Anita; Jairath, Vipul; Osterman, Mark; Akukwe, Lucy; Liu, W. Jerry; Memaj, Arteid; Petersen, AnnKatrin; Jain, Anjali; et al.